Bottom line
RSPH vs RYHIX: the short answer
RSPH (Invesco S&P 500 Equal Weight Health Care ETF) and RYHIX (Health Care Fund) are quite different portfolios: only about 21% of their top holdings (by weight) are shared.
But RYHIX is far broader, holding 135 positions to 63 for RSPH, so beyond the top names it adds exposure RSPH doesn't have.
RSPH is cheaper at 0.4% vs 1.38% — a difference of $98 a year per $10,000 invested.
Over five years, RYHIX returned +5.1% a year vs +4.7% for RSPH.
Updated Nov 19, 2026
RSPH vs RYHIX side by side
| RSPH | RYHIX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | Invesco | Guggenheim |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.4% | 1.38% |
| Annual cost per $10k | $40 | $138 |
| 10-yr cost on $10k (prospectus) | $505 | $1,709 |
| Max front load | None | — |
| 12b-1 fee | — | 0% |
| 1-yr return | +9.3% | +14.4% |
| 5-yr return (annualized) | +4.7% | +5.1% |
| 10-yr return (annualized) | +8.2% | +7.9% |
| Best quarter | +17.5% | +18.7% |
| Worst quarter | −14.3% | −14.4% |
| Net assets (fund) | $766.9M | $19.4M |
| Number of holdings | 63 | 135 |
| Portfolio turnover | 24% | 244% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | RSPH | RYHIX | Difference |
|---|---|---|---|
| 2025 | +9.3% | +14.4% | −5.1% |
| 2024 | −0.8% | +0.6% | −1.4% |
| 2023 | +3.9% | +5.8% | −1.9% |
| 2022 | −9.2% | −11.6% | +2.4% |
| 2021 | +23.0% | +19.2% | +3.8% |
| 2020 | +18.9% | +18.9% | −0.0% |
| 2019 | +25.3% | +22.8% | +2.6% |
| 2018 | −0.3% | +1.6% | −1.9% |
| 2017 | +23.4% | +23.5% | −0.1% |
| 2016 | −4.5% | −9.4% | +4.9% |
Source: Fund prospectus bar charts
Holdings overlap
6 of RSPH's top 25 holdings also appear in RYHIX's top 25.
| Holding | RSPH | RYHIX |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 1.96% | 0.90% |
| Thermo Fisher Scientific Inc. | 1.84% | 1.61% |
| Abbott Laboratories | 1.83% | 1.42% |
| Bristol-Myers Squibb Co. | 1.82% | 1.22% |
| Amgen Inc. | 1.77% | 1.56% |
| AbbVie Inc. | 1.73% | 2.52% |
Source: SEC Form N-PORT
RSPH top 10
- Bio-Techne Corp. — 2.13%
- IQVIA Holdings Inc. — 2.00%
- Baxter International Inc. — 1.99%
- Regeneron Pharmaceuticals, Inc. — 1.96%
- Mettler-Toledo International Inc. — 1.94%
- Charles River Laboratories International, Inc. — 1.93%
- Veeva Systems Inc. — 1.93%
- DaVita Inc. — 1.87%
- Moderna, Inc. — 1.85%
- Thermo Fisher Scientific Inc. — 1.84%
RYHIX top 10
- Eli Lilly & Company — 3.63%
- Johnson & Johnson — 2.88%
- Abbvie Inc — 2.52%
- Unitedhealth Group Inc — 2.22%
- Merck & Company Inc — 2.04%
- Thermo Fisher Scientific Inc — 1.61%
- Amgen Inc — 1.56%
- Abbott Laboratories — 1.42%
- Gilead Sciences Inc — 1.39%
- Vertex Pharmaceuticals Inc — 1.34%
FAQ
What is the difference between RSPH and RYHIX?
Which is cheaper, RSPH or RYHIX?
Should I own both RSPH and RYHIX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.